Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the third leading cause of cancer-related death worldwide. Contemporary advances in systemic and locoregional therapies have led…
The largest study of survival outcomes of pulmonary metastasis–directed local therapy (PM-LT) in adenoid cystic carcinoma (ACC) and the only study to compare survival outcomes…
African American and other Black individuals (referred to as Black people in this article) have a disproportionate cancer burden, including the lowest survival of any…
The American Cancer Society has launched a new population cohort study, VOICES of Black Women, to examine the impact of established health determinants (e.g., smoking,…
The number of people living with a history of cancer in the United States continues to rise because of the growth and aging of the…
The combination of platinum/etoposide and nivolumab improves both progression-free survival and overall survival for patients with ES-SCLC. No new safety signals were observed.
Reirradiation (reRT), defined as administering a course of radiation therapy to a specific area previously irradiated, is an evolving treatment strategy for locoregionally recurrent cancer…
This phase 1 study shows the feasibility and safety of combining dose-escalated radiation (up to 60 Gy) with high-dose nab-paclitaxel for locally advanced pancreatic cancer,…
Over a 20-year period, 4.5% (140 of 3125) of Canadian children who died of cancer were enrolled in early phase studies in their last 90…
Telecytology for rapid on-site assessment is becoming a necessity in cytology practices. The landscape of telecytology is evolving with the availability of different options, each…
This review examines HER2 alterations as emerging therapeutic targets in non–small cell lung cancer, highlighting trastuzumab deruxtecan as the first Food and Drug Administration-approved HER2-direct…
